Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Biochip Blood Test Could Identify Those With An Increased Risk Of Alzheimer’s Disease

XTALKS VITALS NEWS

The biochip-based test runs multiple analyses on a single blood sample, which is a marked improvement over single DNA-based tests.

Tweetables from this article:

Tweet: This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease http://ctt.ec/u7Dvb+This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease.

Tweet: Biochip test detects a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene http://ctt.ec/1UaM9+Biochip test detects a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene.

Share this!

August 9, 2016 | by Sarah Massey, M.Sc.

A new blood test developed by researchers at Randox Laboratories could help identify patients who face a higher risk of developing Alzheimer’s disease. In testing this diagnostic, the research scientists found that the results were as accurate as those from currently-available molecular tests.

“This is the first time that we have used this biochip technology to test for an increased risk of Alzheimer's disease,” said Dr. Emma C. Harte, a research scientist at Randox Laboratories. “This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.”



The biochip-based test runs multiple analyses on a single blood sample, which is a marked improvement over single DNA-based tests. The details of the blood test were presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia.

The biochip test works by detecting a variant of apolipoprotein in a patient’s blood sample, which is produced by the ApoE4 gene. Certain mutations in this gene have previously been associated with an increased risk of developing Alzheimer’s disease.

Just one copy of the ApoE4 gene increases a person’s risk of developing the neurodegenerative disorder three-fold. When both copies of the gene carry the mutation, a patient faces an eight to 12-fold higher risk of Alzheimer’s.

In accessing the accuracy of the biochip blood test, the developers compared the results from 384 samples to those from DNA-based diagnostics. The researchers from Randox Laboratories, along with their collaborators at the Medical University of Vienna, found that all results were consistent across the two test types.

In addition to allowing clinicians to run multiple tests on a single blood sample, the biochip test is also less expensive than the standard test. With results from the biochip blood test in just three hours, the diagnostic could permit doctors to assess Alzheimer’s risk more rapidly than ever before.

“Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine,” said Harte. “This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.”


Keywords: Biochip, Blood Test, Alzheimer's Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.